Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19056056 | COMPOSITIONS AND METHODS FOR NUCLEIC ACID MODIFICATIONS | February 2025 | June 2025 | Allow | 3 | 1 | 0 | No | No |
| 19053424 | CULTURE MEDIUM AND METHOD FOR INDUCING IPSC DIFFERENTIATION TO OBTAIN MACROPHAGES AND USE THEREOF | February 2025 | May 2025 | Allow | 3 | 0 | 1 | Yes | No |
| 19054630 | COMPOSITIONS, SYSTEMS, AND METHODS FOR REGULATION OF HEPATITIS B VIRUS THROUGH TARGETED GENE REPRESSION | February 2025 | April 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19007236 | COMPOSITIONS, SYSTEMS, AND METHODS FOR REGULATION OF HEPATITIS B VIRUS THROUGH TARGETED GENE REPRESSION | December 2024 | March 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 19007278 | COMPOSITIONS, SYSTEMS, AND METHODS FOR REGULATION OF HEPATITIS B VIRUS THROUGH TARGETED GENE REPRESSION | December 2024 | April 2025 | Allow | 4 | 0 | 0 | Yes | No |
| 18999456 | TARGETING THE PVR AXIS USING CAR T CELL THERAPY AND COMBINATIONS | December 2024 | June 2025 | Allow | 5 | 1 | 0 | No | No |
| 18990401 | COMPOSITION FOR REGULATING PRODUCTION OF PROTEINS | December 2024 | March 2025 | Allow | 3 | 0 | 0 | No | No |
| 18988990 | ULTRA-HIGH-CELL-DENSITY MULTICELLULAR TISSUE LIFTING BIOPRINTING DEVICE ASSISTED BY OBLIQUE INCIDENT BULK WAVE AND PRINTING METHOD THEREFOR | December 2024 | April 2025 | Allow | 4 | 0 | 0 | No | No |
| 18983137 | METHODS FOR ISOLATING, CULTURING, AND GENETICALLY ENGINEERING IMMUNE CELL POPULATIONS FOR ADOPTIVE THERAPY | December 2024 | March 2025 | Allow | 3 | 1 | 0 | No | No |
| 18955967 | DRUGS FOR PREVENTION OR TREATMENT OF SEPSIS | November 2024 | January 2025 | Allow | 2 | 0 | 0 | No | No |
| 18945053 | COMPOSITIONS FOR REGULATING PRODUCTION OF AN ANTIBODY LIKE PROTEIN AND RIBONUCLEIC ACID | November 2024 | May 2025 | Allow | 6 | 1 | 0 | No | No |
| 18864911 | SIRNA SPECIFICALLY BINDING TO M2 MACROPHAGE CD206 AND APPLICATION THEREOF | November 2024 | June 2025 | Allow | 7 | 1 | 0 | No | No |
| 18942162 | METHOD OF SEQUENCING A NUCLEIC ACID OF INTEREST | November 2024 | June 2025 | Allow | 7 | 2 | 0 | Yes | No |
| 18933878 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | October 2024 | April 2025 | Allow | 5 | 2 | 0 | No | No |
| 18933499 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | October 2024 | April 2025 | Allow | 5 | 2 | 0 | Yes | No |
| 18933567 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | October 2024 | April 2025 | Allow | 5 | 2 | 0 | Yes | No |
| 18933750 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | October 2024 | April 2025 | Allow | 5 | 2 | 0 | Yes | No |
| 18933645 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | October 2024 | April 2025 | Allow | 5 | 2 | 0 | Yes | No |
| 18933687 | GENE THERAPY FOR RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA USING GENETICALLY CORRECTED AUTOLOGOUS KERATINOCYTES | October 2024 | June 2025 | Allow | 7 | 2 | 0 | No | No |
| 18932078 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | October 2024 | April 2025 | Allow | 5 | 2 | 0 | Yes | No |
| 18931989 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | October 2024 | April 2025 | Allow | 5 | 1 | 0 | No | No |
| 18930307 | METHOD FOR PREVENTING DSRNA BACTERIAL SOLUTIONS FROM BEING DEGRADED BY UVLIGHT AND APPLICATION THEREOF IN CONTROL OF SILVERLEAF WHITEFLIES | October 2024 | March 2025 | Allow | 4 | 1 | 0 | No | No |
| 18928880 | CELL DEATH-INDUCING DFFA-LIKE EFFECTOR B (CIDEB) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | October 2024 | May 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 18926867 | STERILE HUMAN PLACENTAL ALLOGRAFTS HAVING A PLURALITY OF SLITS, OPENINGS, AND/OR FENESTRATIONS FORMED THEREON | October 2024 | March 2025 | Allow | 5 | 1 | 1 | Yes | No |
| 18919051 | ANTIGEN BINDING POLYPEPTIDES | October 2024 | May 2025 | Abandon | 6 | 0 | 1 | Yes | No |
| 18915035 | EFFICIENT SYNTHESIS AND ASSEMBLY METHOD FOR LARGE FRAGMENT DNA BASED ON PROGRAMMABLE NUCLEASE ARGONAUTE | October 2024 | April 2025 | Allow | 6 | 1 | 0 | No | No |
| 18909918 | MODIFIED DOUBLE-STRANDED RNA AGENTS | October 2024 | April 2025 | Allow | 6 | 1 | 0 | No | No |
| 18904578 | ABSOLUTE PRECIPITATION OF EXOSOMES (APEX) ISOLATION | October 2024 | February 2025 | Allow | 4 | 1 | 0 | Yes | No |
| 18899181 | Compositions and Methods of Generating Novel amiRNA | September 2024 | April 2025 | Allow | 7 | 0 | 1 | No | No |
| 18895296 | IMMUNE CELLS DEFECTIVE FOR SUV39H1 | September 2024 | April 2025 | Allow | 7 | 2 | 0 | Yes | No |
| 18889137 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | September 2024 | February 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18885902 | COMPOSITION FOR REGULATING PRODUCTION OF FUSION PROTEINS | September 2024 | May 2025 | Allow | 8 | 1 | 0 | No | No |
| 18886396 | APOPTOTIC CELL MIMIC | September 2024 | April 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 18886134 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | September 2024 | December 2024 | Allow | 3 | 1 | 0 | No | No |
| 18885005 | Compositions and Methods Using CPG Oligonucleotides | September 2024 | April 2025 | Allow | 7 | 1 | 1 | No | No |
| 18824576 | DIFFERENTIATION OF PANCREATIC ENDOCRINE CELLS | September 2024 | June 2025 | Allow | 9 | 3 | 0 | Yes | No |
| 18824588 | DIFFERENTIATION OF PANCREATIC ENDOCRINE CELLS | September 2024 | December 2024 | Allow | 4 | 2 | 0 | No | No |
| 18822374 | APPLICATION OF NANO LAYERED DOUBLE HYDROXIDE IN CARTILAGE REGENERATION AND PREPARATION THEREOF | September 2024 | April 2025 | Allow | 8 | 1 | 1 | No | No |
| 18820652 | DELIVERY AND FORMULATION OF ENGINEERED NUCLEIC ACIDS | August 2024 | March 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 18821068 | DELIVERY AND FORMULATION OF ENGINEERED NUCLEIC ACIDS | August 2024 | February 2025 | Allow | 6 | 1 | 0 | No | No |
| 18820609 | DELIVERY AND FORMULATION OF ENGINEERED NUCLEIC ACIDS | August 2024 | February 2025 | Allow | 5 | 1 | 0 | No | No |
| 18821057 | DELIVERY AND FORMULATION OF ENGINEERED NUCLEIC ACIDS | August 2024 | February 2025 | Allow | 6 | 1 | 0 | No | No |
| 18819737 | RNAi Agents for Inhibiting Expression of Inhibin Subunit Beta E (INHBE), Pharmaceutical Compositions Thereof, and Methods of Use | August 2024 | March 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 18819435 | MODELS OF TAUOPATHY | August 2024 | April 2025 | Allow | 8 | 1 | 0 | No | No |
| 18817528 | CD34 STEM CELL MIMICS | August 2024 | June 2025 | Allow | 10 | 1 | 1 | No | No |
| 18814067 | MODIFIED DOUBLE-STRANDED RNA AGENTS | August 2024 | January 2025 | Allow | 5 | 1 | 0 | No | No |
| 18807591 | COMPOSITIONS AND METHODS FOR INHIBITING LPA EXPRESSION | August 2024 | November 2024 | Allow | 3 | 0 | 1 | No | No |
| 18805534 | TUNING CASCADE ASSAY KINETICS VIA MOLECULAR DESIGN | August 2024 | January 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18805023 | METHODS AND COMPOSITIONS FOR MODULATING A GENOME | August 2024 | May 2025 | Allow | 9 | 1 | 1 | No | No |
| 18800329 | BEAUVERIA BASSIANA STRAIN WITH HIGH ULTRAVIOLET RADIATION RESISTANCE AS WELL AS DIRECTIONAL MUTAGENESIS METHOD THEREFOR AND USE THEREOF | August 2024 | May 2025 | Allow | 10 | 1 | 1 | Yes | No |
| 18801051 | SYNTHETIC SELF-AMPLIFYING MRNA MOLECULES WITH SECRETION ANTIGEN AND IMMUNOMODULATOR | August 2024 | May 2025 | Allow | 9 | 1 | 1 | Yes | No |
| 18799447 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY | August 2024 | December 2024 | Allow | 4 | 1 | 0 | No | No |
| 18797746 | BIOMARKER FOR PREDICTING DRUG RESISTANCE OF BRUTON'S TYROSINE KINASE INHIBITORS AND APPLICATION THEREOF | August 2024 | January 2025 | Allow | 5 | 1 | 0 | No | No |
| 18797392 | IONIZABLE CATIONIC LIPIDS | August 2024 | February 2025 | Allow | 7 | 1 | 0 | No | No |
| 18797394 | TREATMENT OF MST1 RELATED DISEASES AND DISORDERS | August 2024 | March 2025 | Allow | 7 | 1 | 1 | No | No |
| 18796740 | GENE-REGULATING COMPOSITIONS AND METHODS FOR IMPROVED IMMUNOTHERAPY | August 2024 | December 2024 | Allow | 4 | 1 | 0 | No | No |
| 18793716 | APPLICATION OF MECHANICAL-FORCE SENSITIVE MACROPHAGE SUBSET IN PANCREATIC CANCER DIAGNOSIS OR PROGNOSIS EVALUATION | August 2024 | June 2025 | Allow | 10 | 2 | 0 | No | No |
| 18834523 | Recombinant Humanized Collagen Type I Alpha-1 (rhCol1A1), and Expression Vector and Use Thereof | July 2024 | April 2025 | Allow | 8 | 1 | 0 | No | No |
| 18784317 | COMPOSITION FOR REGULATING PRODUCTION OF PROTEINS | July 2024 | February 2025 | Allow | 6 | 1 | 0 | No | No |
| 18782965 | METHOD FOR TREATING C. ACNES BACTERIA-ASSOCIATED DISEASES | July 2024 | May 2025 | Allow | 10 | 1 | 1 | Yes | No |
| 18781699 | RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USE | July 2024 | June 2025 | Allow | 11 | 1 | 1 | No | No |
| 18777597 | SPLIT COMPLEMENTARY BASE EDITING SYSTEMS BASED ON BIMOLECULAR DEAMINASES AND USES THEREOF | July 2024 | April 2025 | Allow | 9 | 0 | 1 | Yes | No |
| 18777787 | COMPOSITIONS AND METHODS FOR TREATING NON-AGE-ASSOCIATED HEARING IMPAIRMENT IN A HUMAN SUBJECT | July 2024 | February 2025 | Allow | 7 | 1 | 0 | No | No |
| 18777187 | COMPOSITIONS AND METHODS FOR TREATING NON-AGE-ASSOCIATED HEARING IMPAIRMENT IN A HUMAN SUBJECT | July 2024 | January 2025 | Allow | 6 | 1 | 0 | No | No |
| 18773146 | COMPOSITION FOR REGULATING PRODUCTION OF PROTEINS | July 2024 | January 2025 | Allow | 6 | 1 | 0 | No | No |
| 18765750 | SAMPLE SPLITTING FOR MULTIPLEXED DETECTION OF NUCLEIC ACIDS WITHOUT AMPLIFICATION | July 2024 | February 2025 | Allow | 7 | 1 | 0 | No | No |
| 18765286 | RESTORATION OF THE CFTR FUNCTION BY SPLICING MODULATION | July 2024 | April 2025 | Allow | 9 | 2 | 0 | Yes | No |
| 18755750 | CRISPR-CAS13 SYSTEM AND USE THEREOF | June 2024 | January 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 18757141 | AAV CAPSID VARIANTS AND USES THEREOF | June 2024 | March 2025 | Allow | 8 | 1 | 1 | No | No |
| 18755160 | mRNA Capping Enzyme And Methods of Use Thereof | June 2024 | July 2025 | Abandon | 12 | 0 | 1 | No | No |
| 18752372 | METHOD FOR SIMPLY CONSTRUCTING TWO-COMPONENT VIRAL VECTOR AND RELATED APPLICATIONS THEREOF | June 2024 | June 2025 | Allow | 11 | 1 | 1 | No | No |
| 18752290 | MODULATION OF GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS | June 2024 | January 2025 | Allow | 7 | 0 | 1 | No | No |
| 18751145 | OPTIMIZED CYP4V2 GENE AND APPLICATION THEREOF | June 2024 | January 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 18751048 | ADVANCED RNA TARGETING (ARNATAR) FOR ANGIOTENSINOGEN | June 2024 | December 2024 | Allow | 6 | 1 | 1 | Yes | No |
| 18745792 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | June 2024 | February 2025 | Allow | 8 | 1 | 0 | Yes | No |
| 18743724 | RECOMBINANT PARTICLE PROTEIN PRODUCT SUITABLE FOR INDUSTRIAL PRODUCTION AND PREPARATION METHOD THEREFOR | June 2024 | May 2025 | Allow | 11 | 2 | 0 | Yes | No |
| 18744370 | LIPID NANOPARTICLE COMPOSITIONS FOR DELIVERY OF MRNA AND LONG NUCLEIC ACIDS | June 2024 | March 2025 | Allow | 9 | 1 | 0 | Yes | No |
| 18741110 | ANTISENSE OLIGONUCLEOTIDE TARGETING ATN1 MRNA OR PRE-MRNA | June 2024 | December 2024 | Allow | 7 | 1 | 0 | Yes | No |
| 18738959 | COMPOSITION FOR REGULATING PRODUCTION OF FUSION PROTEINS | June 2024 | January 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 18739091 | COMPOSITION FOR REGULATING PRODUCTION OF PROTEINS | June 2024 | January 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 18735079 | METHOD FOR ANALYZING CONTENT AND DISTRIBUTION OF MICROPLASTICS IN MARINE CNIDARIA ORGANISMS | June 2024 | January 2025 | Allow | 7 | 1 | 0 | No | No |
| 18731209 | REAGENTS, REAGENT KITS, AND CULTURE MEDIA FOR ACTIVATING AND EXPANDING IMMUNE CELLS AND USES THEREOF | May 2024 | May 2025 | Allow | 12 | 2 | 1 | Yes | No |
| 18715637 | RECOMBINANT COLLAGEN AND PREPARATION METHOD AND USE THEREOF | May 2024 | May 2025 | Allow | 12 | 1 | 0 | Yes | No |
| 18673713 | TRANS-SPLICING MOLECULES | May 2024 | June 2025 | Allow | 13 | 0 | 0 | No | No |
| 18672796 | Targeting Nrip1 to Alleviate Metabolic Disease | May 2024 | May 2025 | Allow | 11 | 0 | 1 | Yes | No |
| 18672959 | TAURINE SUPPLEMENTED CELL CULTURE MEDIUM AND METHODS OF USE | May 2024 | March 2025 | Allow | 9 | 2 | 0 | No | No |
| 18672979 | TAURINE SUPPLEMENTED CELL CULTURE MEDIUM AND METHODS OF USE | May 2024 | March 2025 | Allow | 9 | 2 | 0 | No | No |
| 18669712 | ENDONUCLEASE SYSTEMS | May 2024 | May 2025 | Allow | 11 | 1 | 1 | Yes | No |
| 18660825 | TRANSGENIC CORY | May 2024 | May 2025 | Abandon | 13 | 2 | 1 | Yes | No |
| 18661339 | METHODS OF TREATING OR PREVENTING SPINAL MUSCULAR ATROPHY | May 2024 | October 2024 | Abandon | 5 | 1 | 0 | No | No |
| 18660600 | COMPOUNDS TARGETING PMP22 FOR THE TREATMENT OF CHARCOT-MARIE-TOOTH DISEASE | May 2024 | April 2025 | Allow | 11 | 1 | 1 | Yes | No |
| 18654906 | REAGENTS AND METHODS USED IN DEPROTECTION OF 3'-O-AMINO POLYNUCLEOTIDES | May 2024 | October 2024 | Allow | 5 | 1 | 1 | Yes | No |
| 18649317 | RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USE | April 2024 | November 2024 | Allow | 6 | 1 | 0 | No | No |
| 18646631 | APTAMERS FOR BINDING TO A MEMBRANE-BASED LIPID | April 2024 | December 2024 | Allow | 8 | 1 | 1 | No | No |
| 18644762 | SYSTEMS, METHODS, AND COMPOSITIONS FOR PRODUCTION OF CELLULAR AGRICULTURE PRODUCTS | April 2024 | May 2025 | Allow | 12 | 2 | 1 | Yes | No |
| 18640905 | INHIBITORS OF EXPRESSION AND/OR FUNCTION | April 2024 | March 2025 | Allow | 11 | 1 | 0 | No | No |
| 18630828 | COMPOSITIONS AND METHODS FOR ENHANCING ADOPTIVE T CELL THERAPEUTICS | April 2024 | January 2025 | Allow | 10 | 2 | 1 | Yes | No |
| 18630941 | METHODS OF IDENTIFYING MULTIPLE EPITOPES IN CELLS | April 2024 | August 2024 | Allow | 4 | 0 | 0 | Yes | No |
| 18629638 | PLATELET DIAGNOSTIC IMAGING AGENTS | April 2024 | May 2025 | Abandon | 13 | 1 | 0 | No | No |
| 18625829 | TREATMENT OF MST1 RELATED DISEASES AND DISORDERS | April 2024 | August 2024 | Abandon | 4 | 0 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for group 1630.
With a 31.2% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 18.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Group 1630 is part of Technology Center 1600. This group has examined 97,416 patent applications in our dataset, with an overall allowance rate of 51.2%. Applications typically reach final disposition in approximately 36 months.
Applications in Group 1630 receive an average of 2.06 office actions before reaching final disposition. The median prosecution time is 36 months.
This group-level data aggregates statistics across multiple art units. For more targeted prosecution strategies, review the individual art unit and examiner statistics within this group.
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.